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SUMMARY
Copy number alterations are frequently found in colorectal cancer (CRC), and recur-
rent gains or losses are likely to correspond to regions harbouring genes that promote
or impede carcinogenesis respectively. Gain of chromosome 13q is common in CRC
but, because the region of gain is frequently large, identiﬁcation of the driver gene(s)
has hitherto proved difﬁcult. We used array comparative genomic hybridization to
analyse 124 primary CRCs, demonstrating that 13q34 is a region of gain in 35% of
CRCs, with focal gains in 4% and ampliﬁcation in a further 1.6% of cases. To reduce
the number of potential driver genes to consider, it was necessary to reﬁne the bound-
aries of the narrowest copy number changes seen in this series and hence deﬁne the
minimal copy region (MCR). This was performed using molecular copy-number
counting, identifying IRS2 as the only complete gene, and therefore the likely driver
oncogene, within the reﬁned MCR. Analysis of available colorectal neoplasia data sets
conﬁrmed IRS2 gene gain as a common event. Furthermore, IRS2 protein and mRNA
expression in colorectal neoplasia was assessed and was positively correlated with
progression from normal through adenoma to carcinoma. In functional in vitro exper-
iments, we demonstrate that deregulated expression of IRS2 activates the oncogenic
PI3 kinase pathway and increases cell adhesion, both characteristics of invasive CRC
cells. Together, these data identify IRS2 as a likely driver oncogene in the prevalent
13q34 region of gain/ampliﬁcation and suggest that IRS2 over-expression may pro-
vide an additional mechanism of PI3 kinase pathway activation in CRC.
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Genomic instability is a common feature of the cancer
genome and facilitates tumour progression (Lengauer et al.
1998; Hanahan & Weinberg 2000). Colorectal cancers
(CRC) display two types of genomic instability: microsatel-
lite instability (MSI) and chromosomal instability (CIN).
Microsatellite instability is characterized by the expansion
or contraction of microsatellite repeats and CIN by loss of
heterozygosity and by aneuploidy. Here, the genomic pro-
ﬁles of predominantly CIN tumours were analysed to iden-
tify genes involved in cancer development and progression.
Cancer progression can be viewed as the successive clo-
nal expansion of advantageous genotypes (Nowell 1976).
In a dividing population of tumour cells, genomic altera-
tions – in this case copy number alterations (CNAs) – will
be subject to a number of selective pressures. In this model,
alterations that confer a selective advantage, by promoting
cell growth and survival, will be maintained, whereas dis-
advantageous changes will not. The pattern of recurrent
copy number changes within a given cancer type is there-
fore likely to reﬂect the balance between advantageous and
disadvantageous alterations (Stratton et al. 2009). These
recurrent changes will be superimposed upon selectively
neutral events peculiar to each cancer genome (Chin et al.
2011).
© 2013 The Authors.
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CNAs often involve genes that are critical to cancer progres-
sion: the so-called driver oncogenes (in regions of gain) or
tumour suppressors (in regions of loss; Martin et al. 2007;
Wood et al. 2007; Stratton et al. 2009). The analysis of
CNAs should therefore be able to guide the search for these
critical genes. This approach is challenging, though, because
such CNAs are often large, encompassing tens or hundreds
of genes, the majority of which are presumed to be selec-
tively neutral ‘passengers’ (Tonon et al. 2005). A minority
of cancers, however, show small, focal copy number changes
which fall within the larger, more commonly affected region
of interest (Martin et al. 2007; Leary et al. 2008). Analysis
of amplicon structure in these rare samples can more pre-
cisely deﬁne the ‘minimal affected region’ or ‘minimal copy
region’ (MAR or MCR), reducing the number of candidate
genes that must be considered (Kendall et al. 2007; McCau-
ghan et al. 2010; Poulogiannis et al. 2010a,b).
Most approaches using the concept of MCRs have relied
on a single stage of copy number analysis using array-based
platforms (aCGH/SNP; Martin et al. 2007; Chin et al.
2011). However, such methods typically leave some uncer-
tainty as to the precise boundaries of the MCR and there-
fore fail to fully exploit its potential to pinpoint candidate
driver genes. We have previously shown that molecular
copy-number counting (MCC) is ideally suited to pinpoint-
ing the boundaries of copy number changes, even using very
limited DNA samples (Daser et al. 2006; McCaughan et al.
2008). In the current study, we focus on the MCR on chro-
mosome 13q34 in CRC, identiﬁed by us and others using
array CGH (Lips et al. 2007; Martin et al. 2007). We use
MCC to demonstrate that the smallest MCR contains a sin-
gle whole gene – IRS2. We go on to perform the ﬁrst com-
prehensive analysis of IRS2 gene copy number and
expression in the different stages of CRC progression: from
normal colonic mucosa to adenoma to adenocarcinoma.
We also assess some functional properties of deregulated
IRS2 expression in vitro. These data strongly implicate IRS2
as a driver oncogene within the recurrent 13q34 gain/ampli-
con in colorectal adenocarcinoma.
Material and methods
Colorectal clinical samples
Two independent sample sets were collected from colectomy
surgical specimens. The ﬁrst set of samples (CRC1, n = 119)
was obtained from 94 patients with invasive colorectal pri-
mary carcinoma with or without evidence of metastatic can-
cer deposits. The CRC1 sample set comprised normal
colonic mucosa (n = 22), primary adenocarcinoma (n = 65)
and liver metastatic deposits (n = 32). The second set
(CRC2, n = 133) comprised samples from normal colonic
mucosa (n = 62), hyperplastic polyps (n = 7), adenomatous
polyps (n = 27) and primary adenocarcinoma samples
(n = 37) from a set of 44 patients presenting with synchro-
nous adenoma and invasive carcinoma.
Ethical approval
Ethical approval for all the work conducted was obtained
from Cambridgeshire local research ethics committee (LREC
ref. 04/Q0108/125 and 06/Q0108/307).
Array comparative genome hybridization
Details of the array platform and statistical analysis have
been previously described (Poulogiannis et al. 2010a,b). The
array platform has a mean resolution of 0.97 Mb. The refer-
ence DNA consisted of a pool of mixed female and male
normal leucocyte DNA from 20 unrelated individuals.
Molecular copy-number counting
Molecular copy-number counting has been described previ-
ously in detail (Daser et al. 2006; McCaughan et al. 2008).
Molecular copy-number counting is a digital PCR technique
wherein the sample of interest is dispensed at limiting dilu-
tion into multiple aliquots, so that each aliquot contains less
than one haploid genome’s worth of DNA. A multistep,
multiplexed, single-molecule PCR is then used to count the
number of aliquots containing each sequence of interest. By
using reference sequences, which are assumed to be at nor-
mal copy number, the degree of copy number change can be
estimated. Details of primer design can be found in Data S1.
Bioinformatic meta-analysis of IRS2 gene copy number
and mRNA expression
The signiﬁcance of copy number alteration across 161 colon
cancer samples, including 33 CRC cell lines, was determined
using the GISTIC algorithm with methods described previ-
ously (Beroukhim et al. 2010), using the data deposited at
http://www.broadinstitute.org/tumorscape. Microarray
expression data from The Cancer Genome Atlas (TCGA)
and three previously published data sets (Kaiser et al. 2007;
Hong et al. 2010; Skrzypczak et al. 2010) were downloaded
from TCGA portal (https://tcga-data.nci.nih.gov/tcga/) and
the Oncomine repository (http://www.oncomine.org/). The
distributions of log2 median-centred signal intensities were
plotted using box plots.
Tissue microarray
The construction of the tissue microarray (TMA) has previ-
ously been described (Ibrahim et al. 2011). The TMA con-
tains 419 tissue samples from 64 cases: 23% normal colonic
mucosa, 7% hyperplastic polyps, 15% adenomas, 34% pri-
mary colorectal carcinomas and 21% metastatic CRC sam-
ples. The strength of immunohistochemical staining was
semiquantitatively scored as negative (0), weakly positive in
some cells (1), moderately positive in most cells (2) or
strongly positive in most cells (3) by a consultant histopa-
thologist (AI), who rescored a proportion of samples to con-
ﬁrm reproducibility of scoring. The data were analysed
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a chi-squared test with signiﬁcance set at P < 0.05. Anti-
body speciﬁcity is demonstrated in Figure S2.
Functional analysis of IRS2 over-expression
Solutions and culture conditions are detailed in Data S1.
Transfections were carried out with Lipofectamine 2000
(Life Technologies, Carlsbad, CA, USA) following the manu-
facturer’s guidelines. Successful transfection was conﬁrmed
by Western blotting. The pcDNA3.1Irs2-HA construct was
a kind gift from Douglas Yee (University of Minnesota,
USA; Jackson et al. 2001), and an empty pcDNA3.1 con-
struct was used as a control.
For cell cycle analysis, 1 9 10
6 SW480 cells were ﬁxed in
70% ice-cold ethanol and placed at 20 °C for at least 24 h.
Cells were then washed and resuspended in staining solution
(0.1% Triton, 0.2 mg/ml Rnase A and 0.02 mg/ml propidium
iodide). Ten thousand events were collected on a FACSCali-
bur ﬂow cytometer (BD Biosciences, Franklin Lakes, NJ,
USA). The data were analysed in FLOWJO (Treestar, Ashland,
OR, USA) using the cell cycle analysis protocol (Watson
model). Ct values of <6 were required. The adhesion assay
has previously been described (Zhang et al. 2005). For both
the cell cycle and adhesion analyses, the cells were serum-
starved for 18 h before the addition of IGF-1.
Results
Analysis of DNA gains/ampliﬁcations by aCGH identiﬁes
a relevant MCR on chromosome 13q34
Analysis of the array comparative genome hybridization
(aCGH) data from the two tumour series, including a total
of 124 CRC cases, identiﬁed potential MCRs – deﬁned as
focal changes <5 Mb in size. This analysis highlighted a
region on chromosome 13q34, which was focally gained in
ﬁve cases. Two of these cases were then chosen for further
analysis: case 026 because it showed the narrowest identiﬁed
amplicon and the case 031 due to the degree of copy num-
ber increase (031; Table 1, Figures 1a,b and S1). These focal
gains fell within a larger region that showed DNA copy
number gains in 35% (44/124) of tumours in these two ser-
ies combined; a higher prevalence of 13q34 gains has been
described in the literature (Lips et al. 2007; Martin et al.
2007, and see Discussion).
The smallest amplicon deﬁned by aCGH (case 026;
Figure 1a) in the 13q34 region spanned 2.5 Mb and con-
tained 10 genes. A slightly larger (3.2 Mb) focal gain in this
region was also seen in case 031, encompassing 13 genes;
this case was also notable in that the region was present at
eight copies, relative to normal (diploid) copy number (Fig-
ure 1b). The relatively low resolution of the array CGH
data made it likely that one or both of these small ampli-
cons were in fact smaller than indicated by aCGH, making
it desirable to analyse these two cases at higher resolution.
MCC to reﬁne the 13q34 MCR
Molecular copy-number counting analysis of the amplicons
was used to deﬁne the boundaries of the gains at high reso-
lution. In case 026, MCC reﬁned the amplicon size from
2.5 Mb (containing 10 genes) to 1 Mb; IRS2 was the only
complete protein-coding gene within the reﬁned amplicon
(Figure 1c). Two non-coding RNAs (miRNA AL161431.1
and ncRNA7SK; not shown) also lie within this 1-Mb
amplicon, but their functions are unknown. Similar analysis
of case 031 reﬁned its amplicon size from 3.2 to 2.4 Mb
(Figure 1d), spanning several genes but again including
IRS2. As a result of this high-resolution analysis, IRS2 was
considered to be a strong candidate for a driver oncogene.
IRS2 gene copy number in hyperplastic polyps
Array CGH analysis of a series of colorectal hyperplastic
polyp samples (35 cases) was carried out to determine
whether 13q34 gain occurred in these lesions of very low
malignant potential (Iino et al. 1999; Jass 2003). A gain in
57% of these samples was demonstrated (Table 1).
IRS2 gene copy number and expression in CRC
progression
Bioinformatic meta-analysis of IRS2 gene copy number and
mRNA expression. It is difﬁcult to predict the impact of
the copy number changes, making it necessary to assess the
correlation of IRS2 gene copy number with expression. To
achieve this, a comprehensive meta-analysis of the gene copy
number and mRNA expression levels in TCGA colon cancer
data set was undertaken. This showed that IRS2 was fre-
quently ampliﬁed in CRC and, importantly, that IRS2 gene
copy number was signiﬁcantly positively correlated with
IRS2 mRNA expression (Figure 2a–c).
IRS2 expression is not solely a function of gene copy
number and is likely to be inﬂuenced by a number of
feedback loops and other mutations. Therefore to further
Table 1 The copy number of IRS2 in 124 sporadic colorectal cancers and 35 hyperplastic polyps
Number of cases Loss
Normal
(2 copies) 3 copies 4–5 copies
Ampliﬁcation
(>5 copies)
Focal gains
(<5 Mb)
Carcinoma 2 78 36 6 2 5
Hyperplastic polyp 0 15 17 2 1 3
DNA copy number cut-offs: Loss – <1.75, Normal – 1.75–2.5, three copies – 2.5–3.5, 4–5 copies – 3.5–5.5, Ampliﬁcation – >5.5. Focal gains
were deﬁned as DNA copy number increases (three copies or more) affecting <5 Mb of DNA and encompassing IRS2.
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IRS2 is a candidate oncogene in colon cancer 205explore the transcriptional status of IRS2 in CRC, the
distributions of IRS2 mRNA levels in two independent
microarray data sets were plotted to show that IRS2 expres-
sion is signiﬁcantly higher in colon carcinomas than in nor-
mal mucosa samples (Figure 2d,e; Hong et al. 2010).
The copy numbers and/or expression levels of driver onc-
ogenes are likely to correlate with disease stage (Bertucci
et al. 2004; Garnis et al. 2004). To assess this, bioinformat-
ic analysis and TMA analysis of IRS2 expression during
tumour progression from normal through adenoma to carci-
noma were carried out. A single expression data set contain-
ing samples from all three stages of colorectal carcinoma
formation was available (Skrzypczak et al. 2010). In this
data set, IRS2 mRNA levels showed signiﬁcant increases
through the normal-to-adenoma-to-carcinoma sequence
(Figure 2e).
Immunohistochemical analysis of IRS2 protein expres-
sion. The TMA-IHC analysis showed that all pathological
groups differed signiﬁcantly from normal colon mucosa
with respect to IRS2 expression and demonstrated an
increase in IRS2 expression with progression through the
stages of colorectal carcinoma formation (Figure 3a,b).
Tissue sections from cases 026 and 031 were also stained
and showed an increase in IRS2 expression in the carcinoma
in comparison with the adjacent normal tissue, consistent
with the speciﬁc ampliﬁcation of the IRS2 gene in these
cases (Figure 3c).
Functional analysis of IRS2 over-expression in vitro. IRS
proteins are adaptors in the insulin and IGF signalling cas-
cades (Dearth et al. 2007). These cascades use the oncogenic
PI3K and MAPK pathways and control many characteristics
important to tumour progression including cell proliferation,
adhesion and migration (Figure 4a; Yuan & Cantley 2008).
Differential adaptor protein activation is likely to be one
mechanism by which a single extracellular signal can have
distinct phenotypic effects (Csiszar 2006). In breast cancer,
IRS2 is implicated in metastasis, but not in growth and pro-
liferation (Jackson et al. 2001; Zhang et al. 2004; Byron
et al. 2006; Gibson et al. 2007).
To begin to assess some of the functional implications of
IRS2 over-expression in CRC, three functional in vitro
assays were used. The CRC cell line SW480, derived from a
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Figure 1 (a, b) Array CGH data showing the DNA copy number (normal copy = 1; dotted line) as a function of position on
chromosome 13 for (a) case 026 and (b) case 031. (c, d) Reﬁnement of amplicon boundaries by molecular copy-number counting
(MCC) for (c) case 026 and for (d) case 031. In each case, the aCGH data are indicated by open circles and a dashed line; the MCC
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deﬁned by MCC and aCGH respectively. The positions of protein-coding genes are shown below the axis of (c). All positions are
relative to the NCBI36 human genome assembly.
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206 E. Day et al.primary Dukes’ stage B colon carcinoma, was chosen
because endogenous levels of IRS2 expression were
undetectable. Transient over-expression was achieved
through transfection with pcDNA.IRS2-HA (Jackson et al.
2001) and expression of IRS2 conﬁrmed by immunoblotting
(Figure 4b).
PI3 kinase pathway activation. IRS2 over-expression led
to PI3K pathway activation as evidenced by phosphoryla-
tion of AKT (pAKT) in the absence of upstream activation
(e.g. by IGF-1; Figure 4b, Lane 1). It is challenging to
remove all traces of upstream activators in cultured cells;
however, the cells grown in serum-free media demonstrate
low levels of pAKT (Figure 4b, Lane 2), thus suggesting
minimal upstream activation and therefore ligand-indepen-
dent activation of the PI3K pathway by IRS2 over-expres-
sion. Treatment of the mock-transfected cells with IGF-1
alone led to the phosphorylation of AKT. These cells have
no detectable IRS2 expression, which therefore suggests
signalling is taking place via another adaptor, possibly
IRS1.
MAPK pathway activation was also assessed in a similar
manner, and results suggested constitutive activation of this
pathway in the cell line independent of IGF-1, epidermal
growth factor and IRS2 expression (data not shown).
Cell cycle and adhesion assays. To assess whether IRS2
over-expression inﬂuenced cell cycle and adhesion, in vitro
assays were set up using the transiently transfected SW480
cells. Cell proliferation was assessed by ﬂow cytometry and
cell cycle analysis. Adhesion was determined by the ability
of the cells to adhere to a collagen-coated plate (Zhang
et al. 2005). Migration studies were also carried out using
SW480 cells but yielded inconclusive results (data not
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IRS2 is a candidate oncogene in colon cancer 207shown). Consistent with prior data in breast cancer, the
assays demonstrated that IRS2 over-expression does not
modify cell proliferation but does increase cell adhesion,
whereas IGF-1 stimulation of mock-transfected cells
increased both proliferation and adhesion (Figure 4c,d).
Prior to these assays, the cells were serum-starved to remove
potential upstream activators of the PI3K pathway,
suggesting that increased adhesion in IRS2-over-expressing
cells is ligand independent.
Discussion
Minimal copy region analysis pinpoints IRS2 as a
candidate driver gene in CRC
Minimal copy regions are rare sites of focal DNA copy
number changes seen within larger regions that more fre-
quently show such changes. It is likely that MCRs contain
the genes driving the larger, more prevalent copy number
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bars represent 1 SEM. Raw data are provided in a Supporting
information.
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208 E. Day et al.changes, and data presented here demonstrate how MCRs
can be used to identify candidate driver genes. This analysis
focused on an MCR identiﬁed on chromosome 13q34 in
CRC.
The 13q34 region, within which IRS2 is found, frequently
shows gains in CRC, with a prevalence of up to 85%
reported in the literature (Lips et al. 2007; Martin et al.
2007). Our aCGH analysis shows a lower prevalence of this
gain, with IRS2 copy number increased in 35% of CRCs
analysed, with 4% of cases showing focal gains of <5 Mb.
A further 1.6% of cases contained ampliﬁcations of this
region, which is in keeping with other reports (Parsons et al.
2005; Table 1). Despite their lower prevalence, focal
changes and ampliﬁcations are a strong indication of a func-
tional copy number change (Poulogiannis et al. 2010a; Chin
et al. 2011).
The smallest focal change in the region identiﬁed by
aCGH still contained 10 genes, making it difﬁcult to pro-
pose a candidate driver gene. It was therefore necessary to
reﬁne the boundaries of the amplicon. Molecular copy-
number counting is ideally suited to this application, both
because it can be applied iteratively to reﬁne amplicon
boundaries and because it requires very little sample DNA.
Through this reﬁnement, IRS2 was pinpointed as a potential
driver oncogene in CRC.
Copy number and mRNA and protein expression
analysis support IRS2 as a candidate oncogene
To assess IRS2 as a candidate driver gene, its copy number
and expression were assessed across separate series of
tumours. Our meta-analysis using TCGA demonstrates IRS2
gains in 52.2% of CRCs, with 11.8% showing high-level
ampliﬁcation in this region (Figure 2a). This supports previ-
ous studies, which have proposed IRS2 as a candidate based
on copy number analysis (Lips et al. 2007; Martin et al.
2007; Beroukhim et al. 2010). However, none of these stud-
ies correlated these observations with an assessment of IRS2
expression in CRC. Previous studies characterizing IRS2
expression across human cancers, including CRC, have
failed to show a clear correlation between expression and
the progression from normal tissue to carcinoma
(Mardilovich et al. 2009; Zha et al. 2009). In contrast, our
analysis correlates IRS2 copy number with mRNA expres-
sion (Figure 2c) and demonstrates that expression at both
the mRNA and protein level increases with progression (Fig-
ures 2e and 3a). This suggests that expression of IRS2 may
inﬂuence the progression of CRC and supports data from
Szabolcs et al. (2009) showing that IRS2 inactivation sup-
pressed tumour progression in Pten+/ mice.
IRS2 gene copy number and expression in hyperplastic
polyps do not correlate, suggesting feedback mechanisms
may be important
The analysis of hyperplastic polyps in this study shows that
57% of cases demonstrate a gain in IRS2, compared to
35% of carcinomas. This is unexpected given that these
lesions are not considered immediate precursors of malig-
nancy, although a very small proportion may progress along
the serrated/MSI pathway of colorectal neoplasia. However,
the copy number does not correlate with IRS2 protein levels
seen in this type of lesion – no hyperplastic polyps demon-
strated signiﬁcant over-expression (a score of 3 on the
TMA-IHC analysis; Figure 3a, Table 1). It is therefore pos-
sible that feedback mechanisms, controlling IRS2 protein
levels, are still functioning in these lesions, thus preventing
an increase in IRS2 expression. IRS2 protein levels are con-
trolled by negative feedback from downstream components
of the PI3K pathway, speciﬁcally via mTOR/S6 kinase
(Manning 2004). This is of particular importance in the
context of cancer therapy, as feedback will be lost in
mTOR-targeted chemotherapy (McCampbell et al. 2010).
Therefore, in the light of data presented here and by others
showing IGF-1-independent phosphorylation of AKT by
IRS2 over-expression, mTOR inhibition has the potential to
activate components of the oncogenic PI3 pathway (Dearth
et al. 2006).
IRS2 over-expression in vitro results in AKT
phosphorylation independent of IGF-1 stimulation and
may confer an advantageous phenotype to CRC
The insulin receptor substrate (IRS) family of proteins are
adaptors linking upstream activators, canonically insulin
and IGF-1, to multiple downstream effectors with roles in
normal growth, metabolism and differentiation (Figure 4a;
Dearth et al. 2007). The role of IRS proteins in CRC is
unclear, but a number of studies in breast cancer have sug-
gested a role in proliferation and metastasis of cancer cells
(Zhang et al. 2004; Byron et al. 2006; Gibson et al. 2007;
Mardilovich et al. 2009).
We have shown that IRS2 over-expression in the absence
of an upstream activator, in the CRC cell line SW480, leads
to AKT phosphorylation (Figure 4b). This observation is
supported by previous studies of IRS2 over-expression in
both breast cancer and mouse ﬁbroblasts showing AKT
phosphorylation independent of IGF-1 (Hennige et al. 2000;
Mardilovich & Shaw 2009). This is signiﬁcant as inappropri-
ate AKT activation is oncogenic and a potential therapeutic
target (Hsieh et al. 2011). IRS2 over-expression also
increases CRC cell adhesion to a similar extent to IGF-1
stimulation, but has no effect on cell cycle in this cell line;
this is in agreement with observations in breast cancer and
supports a role of IRS2 in adhesion, but not in proliferation
(Jackson et al. 2001; Gibson et al. 2007). Changes to adhe-
sion, both increases and decreases, are important properties
of metastasizing cancer cells and are involved in invasion,
migration, arrest within the circulation and distant ‘seeding’
of a tumour (Hewitt et al. 2000; Schluter et al. 2006). It is
possible that proliferation stimulated by IGF-1 is mediated
by IRS1 in the SW480 cell line. Although the physiological
relevance of the levels of expression seen in these assays
remains to be proven, the results indicate that IRS2
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phenotype upon cancer cells.
IRS2 and PI3 kinase pathway in CRC
The PI3K pathway is frequently dysregulated in CRC, and
this can be a consequence of alterations at any level of the
pathway – from receptor mutations to the deletion of nega-
tive regulators such as PTEN and mutations and subsequent
over-expression of effectors such as AKT (Parsons et al.
2005). Recently, TCGA Network demonstrated in CRC that
high levels of IRS2 expression are mutually exclusive with
IGF2 over-expression and with other mutations in the PI3K
pathway (TCGA 2012). This suggests that IRS2 over-expres-
sion is one mechanism by which the PI3K pathway may be
dysregulated in CRC, and our data support this conclusion.
In summary, we have used high-resolution analysis of the
13q34 amplicon in two CRC cases to pinpoint the gene IRS2
as a potential driver oncogene in this amplicon. We also show
the ﬁrst focused analysis of IRS2 protein and mRNA levels in
colorectal neoplasms, demonstrating its strongly positive
correlation with CRC progression. Preliminary functional
in vitro analysis suggests that, as has been seen in other cancer
types, IRS2 over-expression confers an advantageous pheno-
type on CRC cells. This highlights the need for further work
to address the circumstances in which IRS2 contributes to
CRC progression. Together, these data indicate IRS2 as a
strong candidate oncogene and support recent suggestions
that the IGF1R–IRS2–PI3K axis may be an important thera-
peutic target in a subset of CRC (TCGA 2012).
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Figure S1. Regions of DNA copy number alteration iden-
tiﬁed along chromosome 13 by the aCGH analysis of the
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ative cells.
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